Predictors of hospitalization and death among pre-dialysis patients: A retrospective cohort study

Nephrology Dialysis Transplantation

Volumn 15, Issue 5, 2000, Pages 650-658

  Holland, David C ^a   Lam, Miu ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Chronic renal insufficiency; Morbidity; Mortality; Outcomes; Pre dialysis; Progressive renal insufficiency

Indexed keywords

ANTIHYPERTENSIVE AGENT; CREATININE; HEMOGLOBIN;

ADOLESCENT; ADULT; AGE; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GENDER; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; HYPOALBUMINEMIA; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; NEPHROSCLEROSIS; NONBIOLOGICAL MODEL; PERIPHERAL VASCULAR DISEASE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STROKE;

EID: 0034011821     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.5.650     Document Type: Article

References (38)

1. Canadian Organ Replacement Register. 1994 Annual Report. Don Mills, Ontario, Canadian Institute for Health Information, 1994
2. Strauss MJ, Port FK, Somen C, Wolfe RA. An estimate of the size of the U.S. pre-dialysis population with renal insufficiency and anemia. Am J Kidney Dis 1990; 21: 264-269
3. NIH Consensus Statement. Morbidity and mortality of dialysis. Ann Intern Med 1994; 12: 62-70
4. Jungers P, Zingaff J, Albouze G et al. Late referral to maintenance dialysis: detrimental consequences. Nephrol Dial Transplant 1993; 8: 1089-1093
5. Ratcliffe PJ, Phillips RE, Oliver DO. Late referral for maintenance dialysis. Br Med J 1984; 288: 441-443
6. Innes A, Rowe PA, Burden RP, Morgan AG. Early deaths on renal replacement therapy, the need for early nephrological referral. Nephrol Dial Transplant 1992; 7: 467-471
7. Eadington DW, Craig KJ, Winney RJ. Late referral for R RT: still a common cause of avoidable morbidity. Renal Association, UK April 1994 (abstract)
8. Ifudu O, Darwood M, Homel P, Friedman EA. Excess morbidity in patients starting uremia therapy without prior care by a nephrologist. Am J Kidney Dis 1996; 28: 841-845
9. Sesso R, Belasco AG, Ajzen H. Late diagnosis of chronic renal failure. Braz J Med Biol Res 1996; 29: 1473-1478
10. Levin A, Lewis M, Mortiboy P et al. Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian centers. Am J Kidney Dis 1997; 29: 533-540
11. Binik YM, Devins GM, Barre PE et al. Live and learn. Patient education delays the need to initiate renal replacement therapy in end-stage renal disease. J Nerv Ment Dis 1993; 181: 371-376
12. Rasgon S, Schwankovsky L, James-Rogens A et al. An interview for employment maintenance among blue-collar workers with end-stage renal disease. Am J Kidney Dis 1993; 22: 403-412
13. Hutchison TA, Duncan CT, MacGibbon B. Predicting survival in adults with end-stage renal disease: an age equivalence index. Ann Intern Med 1982; 96: 417-423
14. Churchill DN, Taylor DW, Cook RJ et al. Canadian Hemodialysis Morbidity Study. Am J Kidney Dis 1992; 3: 214-234
15. Mailloux LU, Napolitano B, Belluci AG, Mossey RT, Vernace MA, Wilkes BM. The impact of co-morbid risk factors at the start of dialysis upon survival of ESRD patients. ASAIO J 1996; 42: 164-169
16. Rocco MV, Jordan K, Burkart JM. The efficiency number as a predictor of morbidity and mortality in peritoneal dialysis patients. J Am Soc Nephrol 1993; 4: 1184-1191
17. Rocco MV, Soucie JM, Reboussin DM, McClellen W. Risk factors for hospital utilization in chronic dialysis patients. J Am Soc Neprol 1996; 7:889-896
18. Avram MM, Mittman N, Bonomini L, Chattapadhyay J, Fein P. Markers for survival in dialysis: a seven year prospective study. Am J Kidney Dis 1995; 26: 209-219
19. Fernandez JM, Carbonell ME, Mazzuchi N, Petrucceli D. Simultaneous analysis of morbidity and mortality factors in chronic hemodialysis patients. Kidney Int 1992; 41: 1029-1034
20. Barrett BJ, Parfrey PS, Morgan J et al. Prediction of early death in end-stage renal disease patients starting dialysis. Am J Kidney Dis 1995; 25: 276-280
21. Khan IFI, Catto JRD, Edwards N, MacLeod AM. Death during the first 90 days of dialysis. a case control study. Am J Kidney Dis 1995; 25: 276-280
22. Lowrie E, Lew N. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482
23. Speigel DM, Anderson M, Campbell U et al. Serum albumin. a marker for morbidity in peritoneal dialysis patients. Am J Kidney Dis 1993; 21: 26-30
24. Speigel DM, Breyer JA. Serum albumin: a predictor of long-term outcome in peritoneal dialysis patients. Am J Kidney Dis 1994; 23: 283-285
25. Canada USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis. Association with clinical outcomes. J Am Soc Nephrol 1996; 7: 198-207
26. Dimitrakov D, Kumchev E, Tilkian E. Study of the effect of recombinant erythropoietin in renal anemia in pre-dialysis patients with chronic renal failure. Folia Med 1994; 36: 31-36
27. Roff D, Schulman G, Steinman TI et al. Effects of recombinant erythropoietin on renal function in chronic renal failure patients. Am J Kidney Dis 1984; 24: 777-784
28. Revicki DA, Brown RE, Feeny DH et al. Health related quality of life associated with recombinant human erythropoietin therapy for pre-dialysis chronic renal failure patients. Am J Kidney Dis 1995; 25: 548-554
29. Albertazzi A, DiLiberato L, Daniele F, Battistel V, Colombi I. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study. Int J Artif Organs 1998; 21: 12-18
30. The U.S. Recombinant Human Erythropoietin Study Pre-dialysis Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in pre-dialysis patients. Am J Kidney Dis 1991; 18: 50-59
31. Austrian multi-center Study Group of r-HuEPO in pre-dialysis patients: Effectiveness and safety of recombinant human erythropoietin in pre-dialysis patients. Nephron 1992; 61: 399-403
32. Foley RN, Parfrey PS, Harrett MB et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61
33. Foley RN, Parfrey PS, Morgan J et al. A randomized controlled trial of complete vs partial correction of anemia in hemodialysis patients with asymptomatic concentric LV hypertrophy or LV dilatation. J Am Soc Nephrol 1998; 9: 208A. Abstract
34. Noth, RH. Diabetic nephropathy: hemodynamic basis and implications for disease management. Ann Intern Med 1989; 110: 795-813
35. Ritz E, Koch E. Morbidity and mortality due to hypertension in patients with renal failure. Am J Kidney Dis 1993; 21 [Suppl. 2]: 113-118
36. Klahr, S. Chronic renal failure management. Lancet 1991; 338: 423-427
37. Hannedouche T, Bouiller M, Caillard S. Absolute cardiovascular risk among nephrology patients. Nephrologie 1998; 19: 197-201
38. Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis 1998; 31: 398-417